Ventilator-associated pneumonia caused by OXA-48-producing Escherichia coli complicated by ciprofloxacin-associated rhabdomyolysis

Journal of Infection and Chemotherapy

Volumn 19, Issue 6, 2013, Pages 1214-1217

  Grisold, Andrea J ^a   Hoenigl, Martin ^a   Ovcina, Ismar ^a   Valentin, Thomas ^a   Fruhwald, Sonja ^a  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

Author keywords

Austria; Carbapenenem resistance; Ciprofloxacin; Escherichia coli; OXA 48; Rhabdomyolysis

Indexed keywords

ATORVASTATIN; C REACTIVE PROTEIN; CIPROFLOXACIN; CREATINE KINASE; DORIPENEM; ERTAPENEM; FOSFOMYCIN; IMIPENEM; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM; TIGECYCLINE;

ADULT; ARTICLE; BACTERIUM CULTURE; BACTERIUM ISOLATE; CASE REPORT; CAUCASIAN; CORONARY ARTERY BYPASS GRAFT; CREATINE KINASE BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ESCHERICHIA COLI; GENE AMPLIFICATION; HOSPITAL ADMISSION; HUMAN; HUMAN TISSUE; LUNG EDEMA; LUNG LAVAGE; MALE; MIDDLE AGED; MINIMUM INHIBITORY CONCENTRATION; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; RHABDOMYOLYSIS; VENTILATOR ASSOCIATED PNEUMONIA;

ANTI-BACTERIAL AGENTS; BETA-LACTAMASES; CIPROFLOXACIN; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; ESCHERICHIA COLI PROTEINS; HUMANS; MALE; MIDDLE AGED; PNEUMONIA, VENTILATOR-ASSOCIATED; RHABDOMYOLYSIS;

EID: 84890860810     PISSN: 1341321X     EISSN: 14377780     Source Type: Journal    
DOI: 10.1007/s10156-013-0628-3     Document Type: Article

References (27)

1. Poirel L, Heritier C, Tolun V, Nordmann P. Emergence of oxacillinase-mediated resistance to imipenem in Klebsiella pneumoniae. Antimicrob Agents Chemother. 2004;48:15-22.
2. Poirel L, Potron A, Nordmann P. OXA-48-like carbapenemases: the phantom menace. J Antimicrob Chemother. 2012;67:1597-606.
3. Morris D, McGarry E, Cotter M, Passet V, Lynch M, Ludden C, et al. Detection of OXA-48 carbapenemase in the pandemic clone Escherichia coli O25b:H4-ST131 in the course of investigation of an outbreak of OXA-48-producing Klebsiella pneumoniae. Antimicrob Agents Chemother. 2012;56:4030-1.
4. Tzouvelekis LS, Markogiannakis A, Psichogiou M, Tassios PT, Daikos GL. Carbapenemases in Klebsiella pneumoniae and other Enterobacteriaceae: an evolving crisis of global dimensions. Clin Microbiol Rev. 2012;25:682-707.
5. Carrer A, Poirel L, Yilmaz M, Akan OA, Feriha C, Cuzon G, et al. Spread of OXA-48-encoding plasmid in Turkey and beyond. Antimicrob Agents Chemother. 2010;54(3):1369-73.
6. Navarro-San Francisco C, Mora-Rillo M, Romero-Gomez MP, Moreno-Ramos F, Rico-Nieto A, Ruiz-Carrascoso G, et al. Bacteraemia due to OXA-48-carbapenemase- producing Enterobacteriaceae: a major clinical challenge. Clin Microbiol Infect 2013;19(2):E72-E729.
7. Gabow PA, Kaehny WD, Kelleher SP. The spectrum of rhabdomyolysis. Medicine (Baltim). 1982;61(3):141-52.
8. Conforti A, Chiamulera C, Moretti U, Colcera S, Fumagalli G, Leone R. Musculoskeletal adverse drug reactions: a review of literature and data from ADR spontaneous reporting databases. Curr Drug Saf. 2007;2(1):47-63.
9. Gupta A, Guron N, Harris M, Bell R. Levofloxacin-induced rhabdomyolysis in a hemodialysis patient. Hemodial Int. 2012;16(1):101-3.
10. Baril L, Maisonobe T, Jasson-Molinier M, Haroche J, Bricaire F, Caumes E. Acute rhabdomyolysis during treatment with ofloxacin: a case report. Clin Infect Dis. 1999;29(6):1598-9.
11. European Committee on Antimicrobial Susceptibility Testing: clinical breakpoints 2012. [Internet]; 2012; cited Oct 1 2012. http://www.eucast.org/ clinical-breakpoints/.
12. Clinical and Laboratory Standards Institute (2011) Performance standards for antimicrobial susceptibility testing: 21st informational supplement. M100(S21). CLSI, Wayne, PA
13. Cuzon G, Naas T, Bogaerts P, Glupczynski Y, Nordmann P. Evaluation of a DNA microarray for the rapid detection of extended-spectrum beta-lactamases (TEM, SHV and CTX-M), plasmid-mediated cephalosporinases (CMY-2-like, DHA, FOX, ACC-1, ACT/MIR and CMY-1-like/MOX) and carbapenemases (KPC, OXA-48, VIM, IMP and NDM). J Antimicrob Chemother. 2012;67(8):1865-9.
14. Potron A, Nordmann P, Lafeuille E, Al Maskari Z, Al Rashdi F, Poirel L. Characterization of OXA-181, a carbapenem-hydrolyzing class D beta-lactamase from Klebsiella pneumoniae. Antimicrob Agents Chemother. 2011;55:4896-9.
15. Zarfel G, Galler H, Feierl G, Haas D, Kittinger C, Leitner E, et al. Comparison of extended-spectrum-beta-lactamase (ESBL) carrying Escherichia coli from sewage sludge and human urinary tract infection. Environ Pollut. 2013;173:192-9.
16. Zarfel G, Hoenigl M, Wurstl B, Leitner E, Salzer HJ, Valentin T, et al. Emergence of carbapenem-resistant Enterobacteriaceae in Austria, 2001-2010. Clin Microbiol Infect. 2011;17(11):E5-8.
17. Zarfel G, Hoenigl M, Leitner E, Salzer HJ, Feierl G, Masoud L, et al. Emergence of New Delhi metallo-beta-lactamase, Austria. Emerg Infect Dis. 2011;17(1):129-30.
18. Hoenigl M, Valentin T, Zarfel G, Wuerstl B, Leitner E, Salzer HJ, et al. Nosocomial outbreak of Klebsiella pneumoniae carbapenemase-producing Klebsiella oxytoca in Austria. Antimicrob Agents Chemother. 2012;56:2158-61.
19. Pedersen TR, Berg K, Cook TJ, Faergeman O, Haghfelt T, Kjekshus J, et al. Safety and tolerability of cholesterol lowering with simvastatin during 5 years in the Scandinavian Simvastatin Survival Study. Arch Intern Med. 1996;156(18):2085-92.
20. Sawant RD. Rhabdomyolysis due to an uncommon interaction of ciprofloxacin with simvastatin. Can J Clin Pharmacol 2009;16(1):e78-e79.
21. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30(2):239-45.
22. Petitjeans F, Nadaud J, Perez JP, Debien B, Olive F, Villevieille T, et al. A case of rhabdomyolysis with fatal outcome after a treatment with levofloxacin. Eur J Clin Pharmacol. 2003;59(10):779-80.
23. Sanjith S, Raodeo A, Clerk A, Pandit R, Karnad DR. Moxifloxacin-induced rhabdomyolysis. Intensive Care Med. 2012;38(4):725.
24. Qian Q, Nasr SH, Akogyeram CO, Sethi S. Myoglobin-associated acute kidney injury in the setting of ciprofloxacin administration. Am J Kidney Dis. 2012;59(3):462-6.
25. Hsiao SH, Chang CM, Tsao CJ, Lee YY, Hsu MY, Wu TJ. Acute rhabdomyolysis associated with ofloxacin/levofloxacin therapy. Ann Pharmacother. 2005;39(1):146-9.
26. Hootkins R, Fenves AZ, Stephens MK. Acute renal failure secondary to oral ciprofloxacin therapy: a presentation of three cases and a review of the literature. Clin Nephrol. 1989;32(2):75-8.
27. George P, Das J, Pawar B, Badyal D. Gatifloxacin-induced rhabdomyolysis. J Postgrad Med. 2008;54(3):233-4.